Drugs used to treat thrombocytopenia in patients with myelodysplastic syndrome (MDS) do not cause disease progression or leukaemic transformation as previously feared, new findings suggest. A trial of the thrombomimetic drug romiplostim in patients with lower risk MDS was terminated early in 2011 after transient increases were seen in blast cell counts and suggestions of ...
Renewed hope for thrombomimetic drugs in myelodysplastic syndrome
By Michael Woodhead
13 Mar 2018